Six months follow-up study on health care workers on persistence of antibodies to SARS-CoV-2 after covishield vaccination
Journal of Evolution of Medical and Dental Sciences
; 11(12):884-887, 2022.
Article
in English
| CAB Abstracts | ID: covidwho-2326281
ABSTRACT
BACKGROUND:
Efficacy of COVID vaccines has been evaluated in various studies. The interim analysis from four randomized controlled trials in UK, Brazil, and south Africa regarding efficacy of two doses of the vaccine was found to be 70.4% (95.8% CI 54.8-80.6). There is a limited data on follow-up Ab titer post vaccination. Hence, the current study is first of its kind with the objective to determine vaccine long term efficacy and its determinants.METHODS:
Health Care Workers (HCW) from Apollo Multispeciality Hospitals, Kolkata who underwent Covishield vaccination from January 2021 to April 2021 were included in the study. Serological testing was done prior to first and second dose of vaccinations, and additionally around six months post second dose.RESULTS:
Between January 2021 to April 2021, 2032 HCW, with predominant age of less than 30 years (44.83%) and male gender (61.96%) undergoing Covishield vaccination were enrolled. Antibodies were detected in 953 (46.9%) individuals prior to first dose, 1449 out of 1495 (96.9%) remained positive prior to second dose and 465 out of 504 (92.3%) HCW after 6 months and remaining 39 (7.7%) either had lost or never had antibodies in their blood. The mean +or- SD value of first, second and third antibodies were 2.35 +or- 3.10, 10.46 +or- 4.84 and 8.75 +or- 4.88 respectively.CONCLUSIONS:
This study provides long observation period, covering the complete progress of the pandemic which provides a "real-life" picture of the antibody level dynamics over time, and after vaccination.
Host Resistance and Immunity [HH600]; Prion; Viral; Bacterial and Fungal Pathogens of Humans [VV210]; Human Immunology and Allergology [VV055]; human diseases; vaccination; immunization; vaccines; antibodies; viral diseases; coronavirus disease 2019; disease prevention; health protection; health care workers; randomized controlled trials; efficacy; immune response; immune sensitization; man; Severe acute respiratory syndrome coronavirus 2; West Bengal; India; Homo; Hominidae; primates; mammals; vertebrates; Chordata; animals; eukaryotes; Severe acute respiratory syndrome-related coronavirus; Betacoronavirus; Coronavirinae; Coronaviridae; Nidovirales; positive-sense ssRNA Viruses; ssRNA Viruses; RNA Viruses; viruses; Commonwealth of Nations; lower-middle income countries; medium Human Development Index countries; South Asia; Asia; secondary vaccination; SARS-CoV-2; viral infections; immunity reactions; immunological reactions
Full text:
Available
Collection:
Databases of international organizations
Database:
CAB Abstracts
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Topics:
Vaccines
Language:
English
Journal:
Journal of Evolution of Medical and Dental Sciences
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS